{"title":"Doxycycline Prophylaxis in Adolescent Patients Treated With MEK Inhibitors.","authors":"Faith Cormier, Irene Lara-Corrales, Rebecca Levy","doi":"10.1111/pde.15996","DOIUrl":null,"url":null,"abstract":"<p><p>Mitogen-activated protein kinase inhibitors (MEKi) are used to treat various conditions, including plexiform neurofibromas, brain tumors, and cancers. Our study aimed to determine whether doxycycline prophylaxis could reduce the frequency and/or severity of acneiform eruptions and paronychia, common side effects of MEKi. Our retrospective study included data from 43 patients aged 12 to 18 years, who received MEKi treatment at the Hospital for Sick Children, Toronto, Canada, between 2010 and 2023. We found that while doxycycline prophylaxis did not significantly impact the frequency or severity of acneiform eruptions (based on CTCAE grading), it appeared to be associated with fewer MEKi discontinuations due to skin toxicities and decreased rates of paronychia.</p>","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.15996","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mitogen-activated protein kinase inhibitors (MEKi) are used to treat various conditions, including plexiform neurofibromas, brain tumors, and cancers. Our study aimed to determine whether doxycycline prophylaxis could reduce the frequency and/or severity of acneiform eruptions and paronychia, common side effects of MEKi. Our retrospective study included data from 43 patients aged 12 to 18 years, who received MEKi treatment at the Hospital for Sick Children, Toronto, Canada, between 2010 and 2023. We found that while doxycycline prophylaxis did not significantly impact the frequency or severity of acneiform eruptions (based on CTCAE grading), it appeared to be associated with fewer MEKi discontinuations due to skin toxicities and decreased rates of paronychia.
期刊介绍：
Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
